Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on BioNano Genomics (NASDAQ:) Inc on Sunday, setting a price target of 15, which is approximately 35.75% above the present share price of $11.05.
DeGeeter expects BioNano Genomics Inc to post earnings per share (EPS) of -$0.08 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in BioNano Genomics, with an average price target of $10.94.
The analysts price targets range from a high of $15 to a low of $0.75.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.2 million and a net profit of -$10.23 million. The company’s market cap is $3 billion.
According to TipRanks.com, Oppenheimer analyst Kevin DeGeeter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 70.0% and a 67.88% success rate.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.